Month: March 2026

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Extends Company Cash Runway into Mid-2028Financing Expected to Fund Completion of Phase 2 Ovarian Cancer TrialFinancing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non-Convertible Debt FinancingTARPON SPRINGS, Fla., March 6, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that it has closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory notes: (i) a promissory note in the original principal amount of $10,930,000 and (ii) a secured promissory...

CORRECTION vol2: Eesti Energia Group Unaudited Results for 2025

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Correction has been made to the consolidated interim income statement: comparative periods for 25H2 and 24H2 have been added. — Sales Revenues and Profitability In 2025, the Baltic energy sector experienced significant developments and challenges, both of which had a major impact on energy security and prices. The energy market, which was previously stable and predictable, has undergone rapid changes in recent years, with prices becoming increasingly volatile. In 2025 sales revenue totalled EUR 1,646.9 million, an 8% decrease year-on-year. EBITDA declined to EUR 317.2 million, an 20% decrease year-on-year. Reported net loss for the year was EUR 82.6 million (EUR –95.5 million year-on-year). The net loss for 2025 includes asset impairments in the amount of EUR 197.6 million, of which EUR 194.5 million are related to oil production...

VEON and JazzWorld Advance Pakistan’s Digital Financial Future with Acquisition of TPL Insurance

Written by Customer Service on March 6, 2026. Posted in Mergers And Acquisitions.

Acquisition to further financial inclusion through integrated digital financial services ecosystem Dubai, New York and Karachi – March 6, 2026 – VEON Ltd. (Nasdaq: VEON, “VEON”), a global digital operator, today announced that its subsidiary Jazz International Holding Limited (“JIH”) has entered into a definitive agreement to acquire a controlling stake in TPL Insurance Limited (“TPL Insurance”), a publicly listed insurance firm in Pakistan. The transaction, which marks a new milestone for VEON’s growing digital financial services portfolio in one of its most dynamic growth markets, is expected to close in mid-2026, subject to regulatory approvals. TPL Insurance, a digital-first insurance provider in Pakistan, offers auto, health, fire and property insurance products through its well-established distribution capabilities, and holds a general...

Virtuix Rings the Nasdaq Closing Bell Celebrating its Listing on the Nasdaq Global Market

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Company Highlights Recent Financial and Operational Momentum Following Third Quarter and Nine-Month Fiscal 2026 Results AUSTIN, Texas., March 06, 2026 (GLOBE NEWSWIRE) — Virtuix Inc. (NASDAQ: VTIX), a leading developer of full-body virtual reality systems, celebrated the ringing of the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York City on March 5, 2026. The ceremony recognized Virtuix’s listing on the Nasdaq Global Market under the ticker symbol “VTIX,” which began trading on January 27, 2026. Virtuix Founder, Chief Executive Officer, and Chairman Jan Goetgeluk participated in the ceremony alongside Nasdaq officials, members of the Virtuix Board of Directors and management team, employees, and guests. A replay of the Nasdaq Closing Bell ceremony is available here. “We were honored to ring the Nasdaq Closing...

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Written by Customer Service on March 6, 2026. Posted in Earnings Releases And Operating Results.

– 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 – – On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 – – Dosing in Phase 2 trial of atebimetinib + Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 – – Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 – NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) — Immuneering...

GXO Appoints Mark Suchinski as Chief Financial Officer

Written by Customer Service on March 6, 2026. Posted in Public Companies.

Mark SuchinskiGXO Appoints Mark Suchinski as Chief Financial OfficerGREENWICH, Conn., March 06, 2026 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced the appointment of Mark Suchinski as Chief Financial Officer, effective April 1, 2026. Suchinski is a seasoned financial leader with more than three decades in finance, operations and supply chain management, with significant experience in the aerospace and defense sector, a key growth vertical for GXO. He has a proven track record driving enterprise performance improvement in labor productivity, contracting, pricing and sourcing. GXO CEO Patrick Kelleher said, “Mark is an accomplished corporate finance leader with decades of operational and supply chain experience and deep expertise in aerospace...

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Written by Customer Service on March 6, 2026. Posted in Earnings Releases And Operating Results.

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027 Third development candidate, JADE301, nominated; Phase 1 clinical trial expected to commence in the first half of 2027 $336 million of cash, cash equivalents, and investments as of December 31st, 2025 expected to provide runway into the first half of 2028SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO),...

AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update

Written by Customer Service on March 6, 2026. Posted in Earnings Releases And Operating Results.

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration On-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026 Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measures Cash runway through the planned early-2029 topline readouts from both Phase 3 pivotal studies Virtual Investor Day scheduled for March 6, 2026NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,...

Strategic Investor Agrees to $80 Million Investment in the Company at $2.00 Per Share, Preliminary Participation in Management, Followed by Subsequent Crypto Contribution

Written by Customer Service on March 6, 2026. Posted in Public Companies.

HANGZHOU, China, March 06, 2026 (GLOBE NEWSWIRE) — Jiuzi Holdings, Inc. (Nasdaq: JZXN, the “Company” or “Jiuzi”), today announced that it has reached an agreement and executed an investment agreement with a strategic investment institution possessing globally leading influence in the fields of crypto asset investment and Crypto treasury management. Pursuant to the agreement, the strategic investor will initially subscribe for 40 million ordinary shares of the Company at a price of $2.00 per share, representing a total investment amount of $80 million, to be funded in cash. This initial investment was completed and closed today, whereby the strategic investor has preliminarily commenced participation in the Company’s management, and both parties have reached a consensus on the plan to advance the subsequent...

MarketWise Reports Net Revenue of $83.4 Million and Net Income of $14.0 Million for Fourth Quarter 2025; Q4 Billings Increase 42% YoY; Beats FY 2025 Guidance for Billings and CFFO; Raises FY 2026 Guidance; Increases Regular Dividend by 25%, FY 2026 Dividend Target of $1.80 per Class A Share; Board Resumes $50M Share Buyback Program

Written by Customer Service on March 6, 2026. Posted in Dividend Reports And Estimates.

BALTIMORE, March 06, 2026 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for fourth quarter 2025.(1) Fourth Quarter 2025 Highlights(1)Total net revenue was $83.4 million in the fourth quarter 2025 (1)Total Billings were $78.9 million in fourth quarter 2025, a year-over-year increase of 42% Net income was $14.0 million in fourth quarter 2025 Cash from Operating Activities for fourth quarter 2025 improved $18.2 million compared to fourth quarter 2024. On a year to date basis, CFFO improved by $68.1 million compared to the year ended December 31, 2024. Cash and cash equivalents were $70.1 million...

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals